| scholarly article | Q13442814 |
| P2093 | author name string | Martin L Katz | |
| Rebecca E H Whiting | |||
| Cheryl A Jensen | |||
| Jacqueline W Pearce | |||
| Lauren E Gillespie | |||
| Daniel E Bristow | |||
| P2860 | cites work | AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease | Q27324755 |
| Characterization of thoracic motor and sensory neurons and spinal nerve roots in canine degenerative myelopathy, a potential disease model of amyotrophic lateral sclerosis | Q33894360 | ||
| Characterization of intercostal muscle pathology in canine degenerative myelopathy: a disease model for amyotrophic lateral sclerosis | Q33894394 | ||
| Genetic basis and phenotypic correlations of the neuronal ceroid lipofusinoses. | Q34336077 | ||
| Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease). | Q34679086 | ||
| Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis | Q35588896 | ||
| Genetics of the neuronal ceroid lipofuscinoses (Batten disease). | Q36053005 | ||
| Quantitative assessment of the canine pupillary light reflex | Q37095330 | ||
| Pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis | Q37353812 | ||
| Neuronal ceroid lipofuscinosis: impact of recent genetic advances and expansion of the clinicopathologic spectrum | Q38115191 | ||
| Lysosomal storage diseases: from pathophysiology to therapy. | Q38318000 | ||
| Golden Retriever dogs with neuronal ceroid lipofuscinosis have a two-base-pair deletion and frameshift in CLN5. | Q38386636 | ||
| Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections. | Q38616394 | ||
| A frame shift mutation in canine TPP1 (the ortholog of human CLN2) in a juvenile Dachshund with neuronal ceroid lipofuscinosis | Q40333380 | ||
| Assessment of retinal function and characterization of lysosomal storage body accumulation in the retinas and brains of Tibetan Terriers with ceroid-lipofuscinosis | Q45250738 | ||
| Retinal pathology in a canine model of late infantile neuronal ceroid lipofuscinosis | Q46698740 | ||
| Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis | Q48513500 | ||
| Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis | Q48702687 | ||
| Selective presence of acid hydrolases in the interphotoreceptor matrix | Q69426514 | ||
| Proteins of the bovine interphotoreceptor matrix: retinoid binding and other functions | Q69870716 | ||
| Lysosomal enzymes in the interphotoreceptor matrix: acid protease | Q71483149 | ||
| Guidelines for clinical electroretinography in the dog: 2012 update | Q86885801 | ||
| P921 | main subject | gene therapy | Q213901 |
| retinal ganglion cell | Q927337 | ||
| P304 | page(s) | 276-282 | |
| P577 | publication date | 2016-03-31 | |
| P1433 | published in | Experimental Eye Research | Q15754753 |
| P1476 | title | Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease | |
| P478 | volume | 146 |
| Q42370349 | A canine model for neuronal ceroid lipofuscinosis highlights the promise of gene therapy for lysosomal storage diseases |
| Q92122633 | A mixed breed dog with neuronal ceroid lipofuscinosis is homozygous for a CLN5 nonsense mutation previously identified in Border Collies and Australian Cattle Dogs |
| Q33782257 | CLINICAL PROGRESS IN INHERITED RETINAL DEGENERATIONS: GENE THERAPY CLINICAL TRIALS AND ADVANCES IN GENETIC SEQUENCING. |
| Q47786937 | Canine neuronal ceroid lipofuscinoses: Promising models for preclinical testing of therapeutic interventions |
| Q90175159 | Emerging treatments for progressive myoclonus epilepsies |
| Q30846558 | Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression |
| Q90441214 | Mice deficient in the lysosomal enzyme palmitoyl-protein thioesterase 1 (PPT1) display a complex retinal phenotype |
Search more.